Literature DB >> 28537986

An update on lupus animal models.

Wei Li1, Anton A Titov, Laurence Morel.   

Abstract

PURPOSE OF REVIEW: The complexity and heterogeneity of the clinical presentation in systemic lupus of erythematosus (SLE), combined to the inherent limitations of clinical research, have made it difficult to investigate the cause of this disease directly in patients. Various mouse models have been developed to dissect the cellular and genetic mechanisms of SLE, as well as to identify therapeutic targets and to screen treatments. The purpose of this review is to summarize the major spontaneous and induced mouse models of SLE and to provide an update on the major advances they have contributed to the field. RECENT
FINDINGS: Mouse models of SLE have continued to contribute to understand the cellular, signaling and metabolic mechanisms contributing to the disease and how targeting these pathways can provide therapeutic targets. Whenever possible, we discuss the advantage of using one model over the others to test a specific hypothesis.
SUMMARY: Spontaneous and induced models of lupus models are useful tools for the study of the cause of the disease, identify therapeutic targets and screen treatments in preclinical studies. Each model shares specific subsets of attributes with the disease observed in humans, which provides investigators a tool to tailor to their specific needs.

Entities:  

Mesh:

Year:  2017        PMID: 28537986      PMCID: PMC5815391          DOI: 10.1097/BOR.0000000000000412

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  77 in total

1.  Polygenic control of susceptibility to murine systemic lupus erythematosus.

Authors:  L Morel; U H Rudofsky; J A Longmate; J Schiffenbauer; E K Wakeland
Journal:  Immunity       Date:  1994-06       Impact factor: 31.745

2.  Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor.

Authors:  Marton Keszei; Cynthia Detre; Wilson Castro; Erica Magelky; Michael O'Keeffe; Katalin Kis-Toth; George C Tsokos; Ninghai Wang; Cox Terhorst
Journal:  FASEB J       Date:  2013-04-29       Impact factor: 5.191

3.  IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

Authors:  Deborah Herber; Thomas P Brown; Spencer Liang; Deborah A Young; Mary Collins; Kyri Dunussi-Joannopoulos
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 4.  Understanding the epidemiology and progression of systemic lupus erythematosus.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Lacie Scofield; Leslie Reinlib; Glinda S Cooper
Journal:  Semin Arthritis Rheum       Date:  2009-01-10       Impact factor: 5.532

5.  Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Authors:  Andrew L Rankin; Nilufer Seth; Sean Keegan; Tatyana Andreyeva; Tim A Cook; Jason Edmonds; Nagappan Mathialagan; Micah J Benson; Jameel Syed; Yutian Zhan; Stephen E Benoit; Joy S Miyashiro; Nancy Wood; Shashi Mohan; Elena Peeva; Shashi K Ramaiah; Dean Messing; Bruce L Homer; Kyri Dunussi-Joannopoulos; Cheryl L Nickerson-Nutter; Mark E Schnute; John Douhan
Journal:  J Immunol       Date:  2013-09-25       Impact factor: 5.422

6.  A novel isoform of the Ly108 gene ameliorates murine lupus.

Authors:  Marton Keszei; Cynthia Detre; Svend T Rietdijk; Pilar Muñoz; Xavier Romero; Scott B Berger; Silvia Calpe; Gongxian Liao; Wilson Castro; Aimee Julien; Ying-Yu Wu; Dong-Mi Shin; Jaime Sancho; Mercedes Zubiaur; Herbert C Morse; Laurence Morel; Pablo Engel; Ninghai Wang; Cox Terhorst
Journal:  J Exp Med       Date:  2011-03-21       Impact factor: 14.307

7.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

Review 8.  Mechanisms of autoantibody production in systemic lupus erythematosus.

Authors:  Shuhong Han; Haoyang Zhuang; Stepan Shumyak; Lijun Yang; Westley H Reeves
Journal:  Front Immunol       Date:  2015-05-13       Impact factor: 7.561

9.  Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.

Authors:  Li Huang; Yong Kong; Jing Wang; Jie Sun; Qin Shi; Yu-Hua Qiu
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

10.  Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.

Authors:  Andreas Keil; Sean R Hall; Meike Körner; Martin Herrmann; Ralph A Schmid; Steffen Frese
Journal:  Arthritis Res Ther       Date:  2016-10-22       Impact factor: 5.156

View more
  43 in total

Review 1.  The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.

Authors:  Adam J Fike; Irina Elcheva; Ziaur S M Rahman
Journal:  Curr Rheumatol Rep       Date:  2019-01-23       Impact factor: 4.592

Review 2.  Chronic inflammatory diseases, myocardial function and cardioprotection.

Authors:  Antigone Lazou; Ignatios Ikonomidis; Monika Bartekova; Theodora Benedek; George Makavos; Dimitra Palioura; Hector Cabrera Fuentes; Ioanna Andreadou
Journal:  Br J Pharmacol       Date:  2020-02-08       Impact factor: 8.739

3.  Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity.

Authors:  Shinya Tanaka; Wataru Ise; Takeshi Inoue; Ayako Ito; Chisato Ono; Yoshihito Shima; Shuhei Sakakibara; Manabu Nakayama; Kentaro Fujii; Ikuo Miura; Jafar Sharif; Haruhiko Koseki; Pandelakis A Koni; Indu Raman; Quan-Zhen Li; Masato Kubo; Katsunori Fujiki; Ryuichiro Nakato; Katsuhiko Shirahige; Hiromitsu Araki; Fumihito Miura; Takashi Ito; Eiryo Kawakami; Yoshihiro Baba; Tomohiro Kurosaki
Journal:  Nat Immunol       Date:  2020-06-22       Impact factor: 25.606

4.  Polymeric dexamethasone prodrugs attenuate lupus nephritis in MRL/lpr mice with reduced glucocorticoid toxicity.

Authors:  Zhifeng Zhao; Haochen Jiang; Xiaoke Xu; Zhenshan Jia; Rongguo Ren; Kirk W Foster; Xin Wei; Ningrong Chen; Steven R Goldring; Mary K Crow; Dong Wang
Journal:  Nanomedicine       Date:  2022-06-26       Impact factor: 6.096

5.  Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus.

Authors:  Rishi R Goel; Xinghao Wang; Liam J O'Neil; Shuichiro Nakabo; Kowser Hasneen; Sarthak Gupta; Gustaf Wigerblad; Luz P Blanco; Jeffrey B Kopp; Maria I Morasso; Sergei V Kotenko; Zu-Xi Yu; Carmelo Carmona-Rivera; Mariana J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-24       Impact factor: 11.205

Review 6.  Dysregulation of T Follicular Helper Cells in Lupus.

Authors:  John D Mountz; Hui-Chen Hsu; Andre Ballesteros-Tato
Journal:  J Immunol       Date:  2019-03-15       Impact factor: 5.422

7.  Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.

Authors:  Samanta C Funes; Mariana Ríos; Felipe Gómez-Santander; Ayleen Fernández-Fierro; María J Altamirano-Lagos; Daniela Rivera-Perez; Raul Pulgar-Sepúlveda; Evelyn L Jara; Diego Rebolledo-Zelada; Alejandra Villarroel; Juan C Roa; Juan P Mackern-Oberti; Alexis M Kalergis
Journal:  Immunology       Date:  2019-10-07       Impact factor: 7.397

8.  When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Authors:  Jill M Pulley; Rebecca N Jerome; Nicole M Zaleski; Jana K Shirey-Rice; Andrea J Pruijssers; Robert R Lavieri; Somsundaram N Chettiar; Helen M Naylor; David M Aronoff; David A Edwards; Colleen M Niswender; Laura L Dugan; Leslie J Crofford; Gordon R Bernard; Kenneth J Holroyd
Journal:  Assay Drug Dev Technol       Date:  2017-12-01       Impact factor: 1.738

Review 9.  Are lupus animal models useful for understanding and developing new therapies for human SLE?

Authors:  Erica Moore; Chaim Putterman
Journal:  J Autoimmun       Date:  2020-06-11       Impact factor: 7.094

10.  The Lupus Susceptibility Locus Sgp3 Encodes the Suppressor of Endogenous Retrovirus Expression SNERV.

Authors:  Rebecca S Treger; Scott D Pope; Yong Kong; Maria Tokuyama; Manabu Taura; Akiko Iwasaki
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.